Thyroid Nodules: When to Worry, When to Watch

Thyroid nodules are very common — about half of adults have them on ultrasound — and roughly 95% are benign. Evaluation is recommended when a nodule is felt on exam, found incidentally on imaging, or larger than 1 cm. The goal is identifying the small minority that are cancer; most nodules just need periodic follow-up.

What thyroid nodules actually are

A thyroid nodule is a discrete lump within the thyroid gland — solid, cystic (fluid-filled), or mixed. They're extremely common: ultrasound finds nodules in 19–35% of adults overall and up to 50% of adults over 60 [C1][C4]. Most are discovered incidentally on imaging done for an unrelated reason (CT of the chest, carotid ultrasound, neck MRI) or felt by a clinician during routine exam [C3].

The key fact: about 95% of thyroid nodules are benign [C1][C3]. The clinical job is finding the 5% that aren't.

What prompts an evaluation

The 2016 American Thyroid Association guidelines list three triggers for a thyroid nodule workup [C1]:

1. Palpable nodule felt on physical exam
2. Incidental nodule seen on imaging (CT, MRI, PET, ultrasound, carotid duplex)
3. Nodule ≥1 cm on ultrasound

Smaller nodules (under 1 cm) are usually only worked up if they have suspicious features on imaging or in patients with elevated risk (history of head/neck radiation, family history of thyroid cancer, or known genetic syndromes) [C1].

Step one: TSH and ultrasound

The standard workup begins with [C1][C3]:

• TSH measurement. A suppressed TSH (low) means the nodule may be a hyperfunctioning (hot) nodule that produces hormone autonomously. Hot nodules are almost always benign and are evaluated with a radioiodine scan instead of biopsy [C1].
• Diagnostic thyroid ultrasound. This is the most important test. Ultrasound classifies the nodule by composition (solid, cystic, mixed), shape, margins, echogenicity, and the presence of calcifications [C1][C2].

The 2017 ACR Thyroid Imaging Reporting and Data System (TI-RADS) is the standardized way ultrasounds are scored, giving each nodule a category from TR1 (benign) to TR5 (highly suspicious) based on its features [C2]. Higher categories mean a higher chance of cancer and a lower size threshold for biopsy.

When biopsy is recommended

Fine-needle aspiration (FNA) biopsy is the gold standard for distinguishing benign from malignant nodules [C1][C5]. The ATA guidelines recommend FNA based on TI-RADS category and size [C1][C2]:

• High-suspicion (TR5): Biopsy ≥1 cm
• Intermediate-suspicion (TR4): Biopsy ≥1.5 cm
• Low-suspicion (TR3): Biopsy ≥2.5 cm
• Very low suspicion (TR2): Biopsy ≥2.5 cm or follow-up only
• Benign-appearing (TR1): No biopsy needed

These thresholds reflect a balance between catching meaningful cancers and avoiding unnecessary biopsies of nodules that are nearly always benign [C1].

What biopsy results mean (Bethesda categories)

The 2017 Bethesda System classifies FNA results into six categories [C7]:

1. Bethesda I — Non-diagnostic. Repeat the biopsy in 4–6 weeks.
2. Bethesda II — Benign. ~95% accuracy; follow with periodic ultrasound.
3. Bethesda III — Atypia of undetermined significance. Repeat biopsy or molecular testing; 5–15% risk of cancer.
4. Bethesda IV — Follicular neoplasm. Surgical evaluation often needed; 15–30% risk of cancer.
5. Bethesda V — Suspicious for malignancy. Surgery typically recommended; 60–75% cancer risk.
6. Bethesda VI — Malignant. Surgery; ~99% cancer.

Molecular testing on indeterminate (III, IV) results — using gene-expression or mutation panels — can help avoid surgery for nodules that turn out benign [C1][C5].

What to do with a benign nodule

If FNA is benign (Bethesda II), most patients can be followed with periodic ultrasound [C1]:

• High-suspicion features: Ultrasound at 12 months, then every 12–24 months.
• Intermediate or low-suspicion: Ultrasound at 12–24 months.
• Very-low-suspicion: Ultrasound at ≥24 months or as needed.

Significant growth (≥20% in two dimensions or >50% volume change) warrants repeat biopsy [C1]. Persistent benign findings after several stable follow-ups can space out further, eventually to every 2–5 years.

Treatment options

Most benign thyroid nodules need no treatment [C1][C3]:

• Surveillance: The default for asymptomatic benign nodules.
• Surgery: For compressive symptoms (difficulty swallowing or breathing), cosmetic concerns, suspicion for malignancy, or hyperfunctioning nodules causing hyperthyroidism.
• Radioactive iodine ablation: For hot nodules causing hyperthyroidism [C1].
• Levothyroxine suppression: Generally not recommended in iodine-sufficient regions; modest effect on nodule size with potential cardiovascular and bone risks [C1].
• Ethanol ablation / radiofrequency ablation: Emerging non-surgical options for selected symptomatic benign nodules in specialized centers [C4].

Frequently asked questions

Are thyroid nodules dangerous? Most are not. About 95% are benign, slow-growing, and asymptomatic [C1][C3]. The job of evaluation is identifying the small fraction that are cancer or that cause symptoms from size or hormone production.

How long does the workup take? Usually 4–8 weeks from finding the nodule to FNA results. TSH and ultrasound at one visit; if biopsy is indicated, it's typically done within 2–4 weeks; cytology results return in 5–10 days [C1].

Will I need my thyroid removed? Most likely no. The majority of patients with thyroid nodules never need surgery [C1][C3]. Surgery is reserved for malignant, suspicious, or symptomatic nodules.

Does Hashimoto's increase nodule risk? Hashimoto's thyroiditis is associated with a higher prevalence of nodules and a modestly increased risk of thyroid lymphoma (rare). Standard nodule workup applies [C3].

Should I avoid iodized salt if I have nodules? No. Iodized salt does not cause thyroid cancer and is recommended for general thyroid health [C1]. Iodine deficiency, in fact, increases nodule and goiter prevalence [C1].

Bottom line

Thyroid nodules are common, mostly benign, and rarely an emergency [C1][C3]. The workup is structured: TSH and diagnostic ultrasound, TI-RADS scoring, and FNA biopsy when indicated by size and risk features [C1][C2]. Most nodules just need periodic follow-up. If your nodule is biopsied as benign, the long-term plan is usually ultrasound surveillance with intervals widening as stability is confirmed. Bring questions about symptoms, growth, or surgical decisions to a thyroid specialist rather than relying on internet panic.

Sources

1. [C1] Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133. PubMed: 26462967
2. [C2] Tessler FN, Middleton WD, Grant EG, et al. ACR Thyroid Imaging, Reporting and Data System (TI-RADS): white paper of the ACR TI-RADS Committee. J Am Coll Radiol. 2017;14(5):587–595. PubMed: 28372962
3. [C3] American Thyroid Association. Thyroid Nodules — Patient Information. thyroid.org
4. [C4] Durante C, Grani G, Lamartina L, Filetti S, Mandel SJ, Cooper DS. The diagnosis and management of thyroid nodules: a review. JAMA. 2018;319(9):914–924. PubMed: 29509871
5. [C5] Gharib H, Papini E, Garber JR, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules — 2016 Update. Endocr Pract. 2016;22(5):622–639. PubMed: 27167915
6. [C6] NIH MedlinePlus. Thyroid nodules. medlineplus.gov
7. [C7] Cibas ES, Ali SZ. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2017;27(11):1341–1346. PubMed: 29091573

---

For educational purposes only. Not medical advice. Always consult your healthcare provider.